European Commission approves Pelmeg▼® (pegfilgrastim) as a biosimilar treatment to reduce the duration of neutropenia and incidence of febrile neutropenia in adults treated with chemotherapy

Nov 23 2018

FOR EUROPEAN MEDICAL MEDIA ONLY | PDF iconDownload PDF